Nickel Sulfate, Potassium Bromide, and Fumaric Acid
Brand Names: Psorizide Forte
Methodology & AI Transparency ⓘ
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: INDICATIONS PSORIZIDE ® Forte is indicated for the treatment of contact dermatitis due to nickel (metal/jewelry allergy,) dyshidrotic hand/foot eczema, and mild to severe psoriasis.
- 2 Real-world patient consensus: Real-world cohort score of 76% across 19 de-identified Nickel Sulfate, Potassium Bromide, and Fumaric Acid entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $80.19 discount cash to $196.47 walk-in retail (NADAC $1.7700/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Nickel Sulfate, Potassium Bromide, and Fumaric Acid: nausea (7.8%), headache (7.8%), dizziness (5.4%).
Ask our AI Specialists anything about Nickel Sulfate, Potassium Bromide, and Fumaric Acid
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Mechanism, CYP450 Pathways & DailyMed Monograph
INDICATIONS PSORIZIDE ® Forte is indicated for the treatment of contact dermatitis due to nickel (metal/jewelry allergy,) dyshidrotic hand/foot eczema, and mild to severe psoriasis. It has been found to work well with a variety of combination therapies. Eczema, seborrhea and a variety of chronic pruritic inflammatory dermatoses generally respond well also.
CLINICAL PHARMACOLOGY The active ingredients in PSORIZIDE ® Forte are simple biochemical compounds. The exact mechanism of action is unknown; however, it is believed PSORIZIDE ® Forte addresses a primary genetic biochemical defect. 5 FUMARIC ACID is a naturally occurring four carbon organic acid important in the Krebs cycle. This biochemical pathway is of central importance to energy production. Each tablet contains approximately 30 mg fumaric acid (calculated). Fumaric Acid has many uses, including use as a food additive (GRAS) and as a chelating agent.
With Elimination kinetics span 8 to 14 hours per Nickel Sulfate, Potassium Bromide, and Fumaric Acid clinical pharmacology residence kinetics and Consistent 54%–66% gastrointestinal absorption profile for Nickel Sulfate, Potassium Bromide, and Fumaric Acid bioavailability, Nickel Sulfate, Potassium Bromide, and Fumaric Acid undergoes systemic clearance of nickel sulfate, potassium bromide, and fumaric acid integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–5 hours post-administration of nickel sulfate, potassium bromide, and fumaric acid.
Standard adult regimens span 1 [hp_X]/1 / 1 [hp_X]/1 Tablet, Therapeutic monitoring titration for Nickel Sulfate, Potassium Bromide, and Fumaric Acid (fda prescription therapeutic agent). Prescribers screen specifically against (refer to section on hypersensitivity ); previous anaphylactoid or exfoliative reaction attributed to nickel sulfate, potassium bromide, and fumaric acid, while community micro-logs most frequently note nausea (7.8% of reports), headache (7.8% of reports), fatigue (5.6% of reports).
Verify medication reconciliation lists so Nickel Sulfate, Potassium Bromide, and Fumaric Acid is not inadvertently duplicated with another fda prescription therapeutic agent.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Nickel Sulfate, Potassium Bromide, and Fumaric Acid dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- (Refer to Section on Hypersensitivity )
- Previous anaphylactoid or exfoliative reaction attributed to Nickel Sulfate, Potassium Bromide, and Fumaric Acid
Logged Side-Effect Incidence (19 Reports)
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nickel Sulfate, Potassium Bromide, and Fumaric Acid)
Human clinical trial evidence for Nickel Sulfate, Potassium Bromide, and Fumaric Acid is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7700/unit (~$53.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $196.47 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $80.19 / mo | View logs ↓ |
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Nickel Sulfate, Potassium Bromide, and Fumaric Acid RxNorm Concept ID | RXN-61480255-1781 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $196.47 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $80.19 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Nickel Sulfate, Potassium Bromide, and Fumaric Acid Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Nickel Sulfate, Potassium Bromide, and Fumaric Acid integrating DailyMed SPL (2025-11-20), CMS NADAC ($1.7700/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Nickel Sulfate, Potassium Bromide, and Fumaric Acid community threads and patient logs by age, biological sex, dosage, and treatment duration.